
CLAIMS

1. A compound of general formula (I) including all tautomeric forms, all enantiomers, isotopic variants, and salts and solvates thereof:



(I)

wherein:

R^1 is selected from methyl, fluoromethyl, difluoromethyl, trifluoromethyl, chlorodifluoromethyl, dichlorofluoromethyl, ethynyl and CN; or

R^2 is selected from methyl and CH_2OH;

R^3 is selected from H and methyl; or

R^2 and R^3 together with the carbon atom to which they are attached form a 3- to 10-membered carbocyclic or oxygen-containing heterocyclic ring system, either of which is optionally substituted, in addition to the R^1 group, with one or more substituents selected from OH, halo, C_{1-4} alkyl, C_{1-4} alkyl substituted with one or more OH substituents, and C_{1-4} haloalkyl; or

when R^2 and R^3 together with the carbon atom to which they are attached form a 4- to 6-membered carbocyclic ring substituted, in addition to the R^1 group, with OH, halo, methyl or CH_2OH, R^1 may also be H; or

when R^2 and R^3 together with the carbon atom to which they are attached form a 4- to 6-membered carbocyclic ring, which is unsubstituted apart from the R^1 group; R^1 may also be CH_2OH; or

R^1, R^2 and R^3 together with the carbon atom to which they are attached combine to form

a 5- to 8-membered bridged carbocyclic or heterocyclic ring system optionally substituted with one or more substituents selected from OH, halo, C_{1-4} alkyl and C_{1-4} haloalkyl;

R^4 is H or halo;

each of R^5 and R^7 is independently selected from H, halo, C_{1-3} alkyl and C_{1-3} haloalkyl;

R^6 is selected from halo, CN and C_{1-4} alkyl optionally substituted with one or more substituents selected from halo and OH;

R^8 is methyl or ethyl, either of which is optionally substituted with one or more halogen substituents;

R^9 is OH, CH_2OH or methyl or ethyl, either of which is optionally substituted with one or more halogen substituents; or

R^8 and R^9 together with the carbon atom to which they are attached form either a 3- to 6-membered cycloalkyl or oxygen-containing heterocyclic ring optionally substituted, in addition to the R^{10} group, with one or more substituents selected from OH, F and CH_2OH; or an ethenyl group optionally substituted with one or two halogen substituents;

R^{10} is selected from H, CN, OH, cycloalkyl optionally substituted with OH, and C_{1-4} alkyl optionally substituted with one or more substituents selected from halo, OH and a 3- to 6-membered cycloalkyl or heterocyclic group, either of which is optionally substituted with OH; or

R^8, R^9 and R^{10} together with the carbon atom to which they are attached form a 5- to 8-membered fused or bridged carbocyclic ring system optionally substituted with one or more substituents selected from OH, F and CH_2OH;

provided that:

i. when R^5 and R^7 are H and R^6 is H or F, R^1, R^2, R^3, R^8, R^9 and R^{10} are not all methyl; and

ii. when R^2, R^3, R^8, R^9 and R^{10} are all methyl, R^5, R^6 and R^7 are not all H; and

iii. when R^1 is CN and R^2 and R^3 together with the carbon atom to which they are

attached form a 3- to 10-membered oxygen-containing heterocyclic ring, R^8, R^9 and R^{10} are not all methyl; and

iv. R^9 and R^{10} are not both OH.

2. A compound according to claim 1 wherein either:

R^8 and R^9 together with the carbon atom to which they are attached form a 3- to 6-membered cycloalkyl or oxygen-containing heterocyclic ring substituted, in addition to the R^{10} group, with one or more CH_2OH substituents and optionally with one or more further substituents selected from OH and F; or

R^8 and R^9 together with the carbon atom to which they are attached form a 3- to 6-membered cycloalkyl or oxygen-containing heterocyclic ring optionally substituted, in addition to the R^{10} group, with one or more substituents selected from OH and F; and R^{10} is CN or C_{1-4} alkyl substituted with one or more substituents selected from OH, a 3- to 6-membered cycloalkyl group optionally substituted with OH and a 3- to 6-membered heterocyclic group optionally substituted with OH; or

R^8 and R^9 together with the carbon atom to which they are attached form an ethenyl group optionally substituted with one or two halogen substituents; or

R^8, R^9 and R^{10} together with the carbon atom to which they are attached form a 5- to 8-membered fused or bridged carbocyclic ring system substituted with one or more CH_2OH substituents and optionally with one or more further substituents selected from OH and F.

3. A compound according to claim 2 wherein either:

R^8 and R^9 together with the carbon atom to which they are attached form a 3- to 6-membered cycloalkyl or oxygen-containing heterocyclic ring system which is unsubstituted except for the R^{10} group; and R^{10} is selected from CN and CH_2OH; or

R^8, R^9 and R^{10} together with the carbon atom to which they are attached form a 5- to 8-membered fused or bridged carbocyclic ring system substituted with CH_2OH.

4. A compound according to claim 1 wherein:

R^8 is methyl or ethyl, either of which is optionally substituted with one or more halogen substituents; and

R^9 is OH, CH_2OH or methyl or ethyl, either of which is optionally substituted with one or more halogen substituents; or

R^8 and R^9 together with the carbon atom to which they are attached form a 3- to 6-membered cycloalkyl or oxygen-containing heterocyclic ring optionally substituted, in addition to the R^{10} group, with one or more substituents selected from OH and F, and R^{10} is H, OH or C_{1-4} alkyl optionally substituted with one or more halo substituents; or

R^8, R^9 and R^{10} together with the carbon atom to which they are attached form a 5- to 8-membered fused or bridged carbocyclic ring system optionally substituted with one or more substituents selected from OH and F.

5. A compound according to claim 4 wherein:

R^8 is methyl or ethyl, R^9 is OH or CH_2OH and R^{10} is methyl or ethyl;

R^8 is methyl or ethyl, R^9 is methyl or ethyl and R^{10} is OH or C_{1-4} alkyl substituted with OH; or

R^8, R^9 and R^{10} are all methyl.

6. A compound according to any one of claims 1 to 5 wherein R^1 is methyl, difluoromethyl, trifluoromethyl, ethynyl or CN.

7. A compound according to any one of claims 1 to 6 wherein either:

R^2 is methyl and/or R^3 is H or methyl; or

R^2 and R^3 together with the carbon atom to which they are attached form a 3- to 6-membered cycloalkyl or oxygen-containing heterocyclic ring system, optionally substituted, in addition to R^1, with one or more substituents selected from OH, halo, C_{1-4} alkyl and C_{1-4} haloalkyl; or

R^1 is H and R^2 and R^3 together with the carbon atom to which they are attached form a 4- to 6-membered carbocyclic ring substituted with OH; or

R^1 is trifluoromethyl; and R^2 and R^3 together with the carbon atom to which they are attached form a cyclopropyl ring which is unsubstituted except for R^1.

8. A compound according to any one of claims 1 to 7 wherein:

R^4 is H; and/or
each of R^5 and R^7 is H; and/or
R^6 is halo, CN, CH_3, CF_3, CHF_2, CH_2F or CH_2OH.

9. A compound according to any one of claims 1 to 8 wherein R^8 is methyl or ethyl, especially methyl; and R^9 is methyl, CH_2OH or OH; or
R^8 and R^9 are each independently methyl or ethyl; or

R^8 and R^9 together with the carbon atom to which they are attached form a 3- to 6-membered cycloalkyl or oxygen-containing heterocyclic ring, wherein the ring is unsubstituted except for the R^{10} moiety and is selected from cycloalkyl rings and heterocyclic rings having a single ring oxygen atom.

10. A compound according to any one of claims 1 or 4 to 9, wherein R^{10} is selected from CN, cyclopropyl, cyclobutyl, unsubstituted methyl or methyl substituted with one or more substituents selected from fluoro, OH and a 3- to 6-membered cycloalkyl or heterocyclyl group.

11. A compound according to any one of claims 1 to 10 wherein R^8 and R^9 together with the carbon atom to which they are attached form a cyclopropyl, cyclobutyl, cyclopentyl or oxetanyl ring, which is either unsubstituted except for the R^{10} group or has a single CH_2OH substituent in addition to the R^{10} group; and R^{10} is methyl, CH_2OH, trifluoromethyl or cyano.

12. A compound according to any one of claims 1 to 11 wherein R^8, R^9 and R^{10} together with the carbon atom to which they are attached form a bridged ring system such as bicyclo[1.1.1]pentane, bicyclo[2.1.1]hexane or bicyclo[2.2.1]heptane, wherein the ring is unsubstituted or is substituted with a single CH_2OH substituent.

13. A compound according to claim 1 selected from:
4-[[2-(4-*tert*-Butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-(1-methylcyclopropyl)pyridine-2-carboxamide (Compound 1);
4-[[2-(4-*tert*-Butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (Compound 1.1);

4-[[2-(4-*tert*-Butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-(1-ethynylcyclopentyl)pyridine-2-carboxamide (Compound 1.2);
4-[[2-(4-*tert*-Butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-(1-cyanoethyl)pyridine-2-carboxamide (Compound 1.3);
4-[[2-(4-*tert*-Butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-[(1R)-1-cyanoethyl]pyridine-2-carboxamide (Compound 1.3a/b);
4-[[2-(4-*tert*-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-[(1S)-1-cyanoethyl]pyridine-2-carboxamide (Compound 1.3 a/b);
4-[[2-(4-*tert*-Butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-(1-cyano-1-methyl-ethyl)pyridine-2-carboxamide (Compound 1.4);
4-[[2-(4-*tert*-Butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-(1-cyanocyclopropyl)pyridine-2-carboxamide (Compound 1.5);
4-[[2-(4-*tert*-Butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-(1-cyano-2-hydroxy-1-methyl-ethyl)pyridine-2-carboxamide (Compound 1.6);
4-[[2-(4-*tert*-Butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-[(1R)-1-cyano-2-hydroxy-1-methyl-ethyl]pyridine-2-carboxamide (Compound 1.6 a/b);
4-[[2-(4-*tert*-butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-[(1S)-1-cyano-2-hydroxy-1-methyl-ethyl]pyridine-2-carboxamide (Compound 1.6 a/b);
4-[[2-(4-*tert*-Butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 1.7);
4-[[2-[2-Fluoro-5-hydroxy-4-(1-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 2);
N-(1-Cyano-1-methyl-ethyl)-4-[[2-[2-fluoro-5-hydroxy-4-(1-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 2.1);
N-*tert*-Butyl-4-[[2-[4-(1-cyano-1-methyl-ethyl)-2-fluoro-5-hydroxy-phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 2.2);
4-[[2-[4-(1-Cyano-1-methyl-ethyl)-2-fluoro-5-hydroxy-phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 2.3);
N-*tert*-Butyl-4-[[2-[4-(1-cyanocyclopropyl)-2-fluoro-5-hydroxy-phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 2.4);
N-(1-Cyano-1-methyl-ethyl)-4-[[2-[4-(1,1-dimethyl-2-morpholino-ethyl)-2-fluoro-5-hydroxy-phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 2.5);
4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl] amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 2.6);
N-(1-Cyano-1-methyl-ethyl)-4-[[2-[2-fluoro-5-hydroxy-4-(2,2,2-trifluoro-1-hydroxy-1-

methyl-ethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 2.7);
4-[[2-[4-(1-Cyclopropyl-1-hydroxy-ethyl)-2-fluoro-5-hydroxy-phenyl]acetyl] amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 2.8);
4-[[2-[4-(4-Cyanotetrahydropyran-4-yl)-2-fluoro-5-hydroxy-phenyl]acetyl] amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 2.9);
4-[[2-[2-Fluoro-5-hydroxy-4-[2-(trifluoromethyl)oxetan-2-yl]phenyl] acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 2.10);
4-[[2-[2-Fluoro-5-hydroxy-4-(1-hydroxy-1-methyl-propyl)phenyl] acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 2.11);
4-[[2-[2-Fluoro-5-hydroxy-4-[(1S)-1-hydroxy-1-methyl-propyl]phenyl]acetyl] amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 2.11 a/b);
4-[[2-[2-fluoro-5-hydroxy-4-[(1R)-1-hydroxy-1-methyl-propyl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl] pyridine-2-carboxamide (Compound 2.11 a/b);
4-[[2-[5-Hydroxy-4-(1-hydroxy-1-methyl-ethyl)-2-methyl-phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 2.12);
4-[[2-[2-Fluoro-5-hydroxy-4-[1-(hydroxymethyl)cyclobutyl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 2.13);
N-(1-Cyano-1-methyl-ethyl)-4-[[2-[2-fluoro-5-hydroxy-4-[2-(trifluoromethyl)oxetan-2-yl]phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 2.14);
4-[[2-[2-Fluoro-5-hydroxy-4-[4-(hydroxymethyl)tetrahydropyran-4-yl]phenyl]acetyl] amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 2.15);
4-[[2-[2-Fluoro-5-hydroxy-4-[1-(hydroxymethyl)cyclopropyl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 2.16);
4-[[2-(4-*tert*-Butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-(1-cyano-1-methyl-ethyl)-5-fluoro-pyridine-2-carboxamide (Compound 3);
N-(1-Cyanocyclopropyl)-4-[[2-[2-deuterio-6-fluoro-3-hydroxy-4-[2,2,2-trideuterio-1,1-bis(trideuteriomethyl)ethyl]phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 4);
N-(1-Cyano-1-methyl-ethyl)-4-[[2-[2-fluoro-5-hydroxy-4-(1-methylcyclo butyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 5);
N-*tert*-Butyl-4-[[2-(4-*tert*-butyl-5-hydroxy-2-isopropyl-phenyl)acetyl]amino] pyridine-2-carboxamide (Compound 6);
N-*tert*-Butyl-4-[[2-[2-fluoro-5-hydroxy-4-(1-hydroxy-1-methyl-ethyl)phenyl] acetyl]amino]pyridine-2-carboxamide (Compound 7);
4-[[2-(2-Fluoro-5-hydroxy-4-isopropenyl-phenyl)acetyl]amino]-N-[1-(trifluoromethyl) cyclopropyl]pyridine-2-carboxamide (Compound 7.1);

N-*tert*-Butyl-4-[[2-[2-fluoro-5-hydroxy-4-(1-methylcyclopropyl)phenyl] acetyl]amino]pyridine-2-carboxamide (Compound 8);
N-(1-Cyanocyclopropyl)-4-[[2-[2-fluoro-5-hydroxy-4-[1-(trifluoromethyl) cyclopropyl]phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 9);
4-[[2-(4-*tert*-Butyl-2-chloro-5-hydroxy-phenyl)acetyl]amino]-N-(1-cyano-1-methyl-ethyl)pyridine-2-carboxamide (Compound 10);
4-[[2-(4-*tert*-Butyl-2-chloro-5-hydroxy-phenyl)acetyl]amino]-N-[1-(trifluoromethyl) cyclopropyl]pyridine-2-carboxamide (Compound 10.1);
4-[[2-(4-*tert*-Butyl-2-chloro-5-hydroxy-phenyl)acetyl]amino]-N-(1-cyanocyclopropyl) pyridine-2-carboxamide (Compound 10.2);
4-[[2-[2-Fluoro-5-hydroxy-4-(3-hydroxy-1,1-dimethyl-propyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 11);
N-(4-Cyanotetrahydropyran-4-yl)-4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 12);
4-[[2-[2-Fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-[3-(trifluoromethyl)oxetan-3-yl]pyridine-2-carboxamide (Compound 12.1);
4-[[2-[2-Fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-[(1S,2S)-2-hydroxycyclopentyl]pyridine-2-carboxamide (Compound 12.2);
4-[[2-[2-Fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-(2-hydroxy-1,1-dimethyl-ethyl)pyridine-2-carboxamide (Compound 12.3);
4-[[2-[2-Fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-[1-(hydroxymethyl)cyclobutyl]pyridine-2-carboxamide (Compound 12.4);
4-[[2-[2-Fluoro-5-hydroxy-4-(4-hydroxytetrahydropyran-4-yl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 13);
4-[[2-[2-Chloro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 14);
4-[[2-[5-Hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)-2-methyl-phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 14.1);
N-(3,3-Difluoro-1-methyl-cyclobutyl)-4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 15);
4-[[2-[2-Chloro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-(1,1-dimethylprop-2-ynyl)pyridine-2-carboxamide (Compound 15.1);
4-[[2-[2-Chloro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-(3,3-difluoro-1-methyl-cyclobutyl)pyridine-2-carboxamide (Compound 15.2);
4-[[2-[2-Chloro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-[1-

(difluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 15.3);
N-[1-(Difluoromethyl)cyclopropyl]-4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 15.4);
N-(1,1-Dimethylprop-2-ynyl)-4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 16);
4-[[2-[2-Fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-(4-methyltetrahydropyran-4-yl)pyridine-2-carboxamide (Compound 16.1);
N-(1-Cyano-1-methyl-ethyl)-4-[[2-[2-fluoro-5-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 16.2);
4-[[2-[2-Fluoro-5-hydroxy-4-(2-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]-N-(4-methyltetrahydropyran-4-yl)pyridine-2-carboxamide (Compound 16.3);
4-[[2-[2,6-Difluoro-3-hydroxy-4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 16.4);
4-[[2-[2-Fluoro-5-hydroxy-4-[2,2,2-trifluoro-1-(hydroxymethyl)ethyl]phenyl]acetyl] amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 17);
4-[[2-[2-Chloro-6-fluoro-3-hydroxy-4-(1-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 18);
4-[[2-[2-Chloro-5-hydroxy-4-(1-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 19);
4-[[2-[2-Fluoro-5-hydroxy-4-(2-hydroxy-1-methyl-ethyl)phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 20);
4-[[2-[2-Fluoro-5-hydroxy-4-[(1S)-2-hydroxy-1-methyl-ethyl]phenyl]acetyl] amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 20a/b);
4-[[2-[2-fluoro-5-hydroxy-4-[(1R)-2-hydroxy-1-methyl-ethyl]phenyl]acetyl]amino]-N-[1-(trifluoromethyl)cyclopropyl] pyridine-2-carboxamide (Compound 20a/b);
and salts and solvates of the above.

14. The compound of claim 13, which is 4-[[2-(4-*tert*-Butyl-2-fluoro-5-hydroxy-phenyl)acetyl]amino]-N-(1-cyanocyclopropyl)pyridine-2-carboxamide (Compound 1.5); or a salt or solvate thereof.

15. The compound of claim 14, which is N-(1-Cyanocyclopropyl)-4-[[2-[2-deuterio-6-fluoro-3-hydroxy-4-[2,2,2-trideuterio-1,1-bis(trideuteriomethyl) ethyl]phenyl]acetyl]amino]pyridine-2-carboxamide (Compound 4); or a salt or solvate thereof.

16. The compound of claim 13, which is 4-[[2-[2-Fluoro-5-hydroxy-4-[2,2,2-trifluoro-1-(hydroxymethyl)ethyl]phenyl]acetyl] amino]-N-[1-(trifluoromethyl)cyclopropyl]pyridine-2-carboxamide (Compound 17); or a salt or solvate thereof.

17. The compound of claim 13, which is 4-[[2-(4-*tert*-Butyl-2-chloro-5-hydroxy-phenyl)acetyl]amino]-N-[1-(trifluoromethyl) cyclopropyl]pyridine-2-carboxamide (Compound 10.1); or a salt or solvate thereof.

18. A compound according to any one of claims 1 to 17 for use in the treatment or prophylaxis of diseases and conditions affected by modulation of TMEM16A.

19. The use of a compound according to any one of claims 1 to 17 in the manufacture of a medicament for the treatment or prophylaxis of diseases and conditions affected by modulation of TMEM16A.

20. A method for the treatment or prophylaxis of diseases and conditions affected by modulation of TMEM16A, the method comprising administering to a patient in need of such treatment an effective amount of a compound according to any one of claims 1 to 17.

21. A compound for use, a use or a method according to any one of claims 18 to 20, wherein the diseases and conditions affected by modulation of TMEM16A are selected from respiratory diseases and conditions, dry mouth (xerostomia), intestinal hypermobility, cholestasis and ocular conditions.

22. A pharmaceutical composition comprising a compound according to any one of claims 1 to 17 and a pharmaceutically acceptable excipient.